Novavax Inc. (NVAX)
7.05
-0.42 (-5.62%)
At close: Apr 24, 2025, 3:59 PM
7.12
0.92%
Pre-market: Apr 25, 2025, 06:50 AM EDT
Novavax Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|
| License Fees Revenue | 9.9M | 82.32M | 529.16M | 2.23M | 287.79M | 626.09M | 55.45M | 585.63M |
| License Fees Revenue Growth | -87.97% | -84.44% | +23618.42% | -99.22% | -54.03% | +1029.01% | -90.53% | n/a |
| Product Revenue | 38.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| Europe Revenue | 268.36M | 823.54M |
| Europe Revenue Growth | -67.41% | n/a |
| North America Revenue | 29.96M | 194.48M |
| North America Revenue Growth | -84.60% | n/a |
| Rest Of The World Revenue | 233.07M | 536.94M |
| Rest Of The World Revenue Growth | -56.59% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 70.75M | 101.3M | 82.3M | 155.24M | 107.46M | 93.72M | 112.53M | 161.66M | 122.88M | 108.16M | 95.99M | 84.21M | 77.79M | 73.16M | 63.19M | 61.31M | 56.88M | 17.72M | 9.38M | 8.18M | 7.9M | 9.61M | 8.73M | 9.22M | 8.31M | 8.22M | 8.65M | 8.54M | 8.12M | 8.94M | 8.85M | 8.34M | 13.56M | 14.1M | 10.53M | 8.85M | 9.06M | 7.09M | 5.84M |
| Selling, General, and Administrative Revenue Growth | -30.16% | +23.09% | -46.99% | +44.46% | +14.66% | -16.72% | -30.39% | +31.57% | +13.61% | +12.68% | +13.99% | +8.25% | +6.33% | +15.78% | +3.06% | +7.80% | +221.01% | +88.92% | +14.66% | +3.56% | -17.77% | +10.01% | -5.33% | +11.01% | +1.03% | -4.95% | +1.31% | +5.20% | -9.19% | +0.99% | +6.09% | -38.45% | -3.85% | +33.92% | +18.93% | -2.30% | +27.82% | +21.31% | n/a |
| Research and Development Revenue | 87.16M | 106.95M | 92.68M | 164.7M | 106.23M | 219.47M | 247.1M | 257.85M | 304.3M | 289.65M | 383.48M | 962.96M | 408.19M | 570.68M | 592.67M | 401.2M | 294.09M | 34.85M | 16.89M | 29.34M | 18.61M | 30.42M | 35.47M | 43.41M | 41.33M | 44.54M | 44.51M | 49.66M | 41.86M | 39.26M | 37.65M | 51.1M | 52.98M | 64.9M | 68.95M | 75.9M | 27.92M | 25.04M | 25.89M |
| Research and Development Revenue Growth | -18.50% | +15.39% | -43.73% | +55.04% | -51.60% | -11.18% | -4.17% | -15.26% | +5.06% | -24.47% | -60.18% | +135.91% | -28.47% | -3.71% | +47.72% | +36.42% | +743.96% | +106.25% | -42.42% | +57.65% | -38.81% | -14.25% | -18.29% | +5.05% | -7.22% | +0.06% | -10.36% | +18.62% | +6.62% | +4.27% | -26.31% | -3.55% | -18.37% | -5.87% | -9.16% | +171.89% | +11.48% | -3.27% | n/a |